City Hill Ventures
Contact Us  
Home About Us Team News
 
   
 

News and Events

 
6.01.15 Ignyta Announces Phase 1 Clinical Trial Data for Entrectinib    read more
4.27.15 Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps    read more
4.21.15 Flex Pharma Data Presented at AAN Platform Session    read more
4.08.15 Ignyta Announces Multiple Presentations at the 2015 AACR Annual Meeting    read more
3.17.15 Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva    read more
2.17.15 Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer    read more
2.05.15 Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Non-Small Cell Lung Cancer    read more
2.04.15 Flex Pharma Announces Closing Of Initial Public Offering    read more
1.28.15 Flex Pharma Announces Pricing Of Initial Public Offering    read more
1.07.15 Independa TV-based Social Engagement and Remote Care Solution to become available for Purchase by Individuals for their Loved Ones    read more
12.29.14 Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma    read more
12.15.14 Ignyta Announces Amendment to License Agreement with Nerviano    read more
12.02.14 Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory    read more
11.18.14 Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics' Conference    read more
11.12.14 Independa Earns Coveted 2015 CES Innovation Award in “Tech for a Better World” Category    read more
10.01.14 Ignyta Secures $31 Million Term Loan Facility from Silicon Valley Bank    read more
9.28.14 Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress    read more
8.04.14 Ignyta and Nerviano Announce License Agreement for Two First-in-Class Kinase Inhibitors    read more
7.21.14 Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of RXDX-101    read more
5.31.14 Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress    read more
5.07.14 Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting    read more
5.01.14 Flex Pharma Cofounder Bruce Bean Elected to National Academy of Sciences    read more
3.17.14 Ignyta Announces Underwriters' Full Exercise of Option to Purchase Additional Shares in Public Offering of Common Stock    read more
3.13.14 Ignyta Announces Pricing of Public Offering of Common Stock    read more
2.27.14 Ignyta Announces Submission of IND for RXDX-101    read more
2.20.14 Ignyta Announces Preliminary Data from RXDX-101 Phase 1 Clinical Trial    read more
1.15.14 Independa Named #1 Technology in Senior Care at CES 2014    read more
1.06.14 Ignyta Receives $10 Million Through Expanded Capital Term Loan from Silicon Valley Bank    read more
12.03.13 Ignyta Announces Completion of $54 Million in Private Placements to Catalyze Precision Medicine for Cancer Patients    read more
11.01.13 Ignyta Completes Merger and Announces License Agreement for the Development of Two Leading Tyrosine Kinase Inhibitors    read more
10.09.13 Independa Closes Initial Series B Round of $2.25 Million     read more
5.20.13 Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine    read more
2.28.13 Ignyta Raises Additional $1M Through Capital Term Loan from Silicon Valley Bank    read more
2.25.13 Ignyta Signs Rheumatoid Arthritis Research Collaboration with Leiden University Medical Center    read more
1.09.13 ‘Small Ball’ Investing as an Alternative Model in Life Sciences    read more
1.02.13 Independa Closes Series A Funding Round, Reaching $5 Million    read more
1.02.13 Latest Venture Funding Deepens Independa’s Ties with LG Electronics    read more
12.31.12 Ignyta Ends 2012 with Oversubscribed, Expanded Series B Financing    read more
12.31.12 City Hill Leads $6M Financing to Pioneer RA Diagnostics at Ignyta    read more
9.17.12 Bionomics Acquires US-Based Cancer Stem Cell Company Eclipse Therapeutics    read more
6.29.12 NexDx Raises $2.6 million in Series B Financing and Capital Term Loan    read more
6.27.12 Inhibrx Announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program    read more
6.02.12 NexDx, Inc. Selected as One of 2012’s “Cool Companies” by San Diego Venture Group    read more
4.25.12 Independa Closes Convertible Note Funding at $2.35 Million    read more
4.17.12 Dyax and Eclipse Therapeutics Announce Oncology Antibody License Agreement    read more
4.16.12 City Hill Ventures, LLC To Present at 2012 Business Development Biotech Conference, April 17     read more
4.11.12 NexDx Signs Exclusive Worldwide License Agreement with UC San Diego To Leverage Epigenetics Discoveries for Early Diagnosis of Rheumatoid Arthritis    read more
3.28.12 Independa Selected by LivHOME, Major National Home Care Provider for Elderly    read more
3.19.12 Independa to Integrate Telcare Glucose Monitoring Into Remote Telehealth Suite for Elderly    read more
3.01.12 Lonza and Eclipse Therapeutics Announce Development and Manufacturing Agreement for Lonza to Conduct Phase 1 Production of Eclipse’s ET-101    read more
2.01.12 Eclipse Therapeutics Appoints Hans Clevers, M.D., Ph.D., and Thomas Kipps, M.D., Ph.D. to Scientific Advisory Board    read more
1.20.12 Entrepreneur Lim Spawns Life Sciences Start-Ups Through City Hill Ventures    read more
1.11.12 Independa Unveils Health Measures – An Easy, Affordable Option for Home Health Monitoring    read more
1.10.12 Independa and LG Team to Provide Industry-First Suite of TV-Based Eldercare Services to Senior Living Market    read more
12.16.11 Independa featured on San Diego Living    read more
12.05.11 Independa Introduces Artemis™ – Integrated Health, Safety and Activity Monitoring for the Independent Elderly    read more
10.26.11 Eclipse Therapeutics Enters Exclusive Assignment and License Agreement to Acquire Biogen Idec’s Cancer Stem Cell Assets    read more
10.24.11 ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology for Therapeutic Antibody Development    read more
9.22.11 Independa Closes $1.6 Million in Seed-Round Funding    read more
8.03.11 Elderly Particularly Vulnerable to Dangers of Heat Waves, Independa Chief Medical Officer Warns    read more
6.28.11 Independa Launches Angela - Social Engagement and Fun for Remote Care Recipients    read more
3.28.11 Eclipse Therapeutics Launches Operations and Secures First Close in Seed Financing for Development of Novel Cancer Stem Cell Drugs    read more
 
 
 
   
 
© 2010 City Hill Ventures, LLC Home    About Us    Team    Portfolio    News    Contact Us
 
Learn More